RAXORULIMOGENE BELZOVACIREPVEC TRANSGENE (IGGL-T2A-.ALPHA.CTLA4-IGGH)
UNII 63SFS9Q5ZB

Substance Identification & Data

This profile provides standardized clinical and technical data for Raxorulimogene Belzovacirepvec Transgene (iggl-t2a-.alpha.ctla4-iggh), uniquely identified by the FDA Unique Ingredient Identifier (UNII) 63SFS9Q5ZB.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
63SFS9Q5ZB
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
RAXORULIMOGENE BELZOVACIREPVEC TRANSGENE (IGGL-T2A-.ALPHA.CTLA4-IGGH)
Official standardized name for this substance within the FDA UNII nomenclature system.
Substance Type
nucleicAcid
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Raxorulimogene Belzovacirepvec Transgene (iggl-t2a-.alpha.ctla4-iggh). Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

RAXORULIMOGENE BELZOVACIREPVEC TRANSGENE (ANTI-CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4) IMMUNOGLOBULIN G1 .GAMMA.1-CHAIN FUSED VIA A SYNTHETIC T2A PEPTIDE WITH HUMAN IMMUNOGLOBULIN KAPPA CHAIN (ANTI-CTL4 ANTIBODY) WITH THE IG.KAPPA. SIGNAL SEQUENCE FOR THE HEAVY CHAIN AND AN ANTI-CD79B LIGHT CHAIN SIGNAL FOR THE LIGHT CHAIN)
RAXORULIMOGENE BELZOVACIREPVEC TRANSGENE (IGGL-T2A-.ALPHA.CTLA4-IGGH)

External Clinical & Regulatory Resources

NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record